EPO and chronic kidney disease: Although it is difficult to make definitive projections of how the single‐dose EPO findings from this study would translate to CKD patients with anemia and hepatic impairment on long‐term daprodustat treatment, routine monitoring of hemoglobin is expected, and doses titrated for each individual.